[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-stroke":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100547151","plaque-characteristics-predict-recurrent-stroke-in-mca-stroke-patients-100547151",false,"NCT06404242","Plaque Characteristics Predict Recurrent Stroke in MCA Stroke Patients","Plaque Characteristics From Vessel Wall Magnetic Resonance Imaging Predict Recurrent Stroke in Ischemic Stroke Patients Due to Middle Cerebral Artery Stenosis","Inclusion Criteria:\n\n* Patients who had a first-time ischemic stroke due to MCA atherosclerosis stenosis more than 50% and admitted to our hospital within 7 days after onset.\n* Patients are more than 45 years old.\n* Patients had HR-MRI and have done the full stroke workup (including carotid duplex scanning, fasting lipid profile, Holter ECG 24 hours, cardiac ultrasound,...)\n\nExclusion Criteria:\n\n* Patients also have stenosis of the carotid artery (more than 50%) or occulsion on the same side of ischemic stroke\n* Patients also have an ischemic stroke in territories other than MCA territory.\n* Patients had any characteristics that suggested other causes for their stenosis, including moyamoya, dissection, and inflammation on their MRI and HR-MRI.\n* Patients with evidence suggestive of cardioembolism (Atrial fibrillation, decreased EF \\\u003C50%, recent heart attack in 3 weeks, rheumatic valvular heart disease, dilated cardiopathy, sick sinus syndrome, infective endocarditis).\n* Any signs suggestive other causes (non atherosclerosis etiology), including autoimmune disease or increased coagulation state.\n* Patients with severe concomitant disease could affect the 6-month follow-up of the patients.","ALL","45 Years","100 Years",{"count":20,"type":21},75,"ESTIMATED","OBSERVATIONAL","The epidemiology of TOAST classification in Asian patients seems to differ due to the higher rates of large-artery atherosclerosis. The complex pathology of atherosclerosis could lead to recurrent stroke, including shear stress on the endothelium, disturbance of the flow, occlusion at the origin of the perforating artery, and other complications (plaque inflammation, plaque hemorrhage, plaque rupture) that could lead to stroke and recurrent stroke. Therefore, The exact determination of the etiology of stroke due to atherosclerosis is the most critical factor for treatment and prognostic. On the other hand, HR-MRI could be a useful imaging modality to evaluate the characteristics of plaque in stroke patients due to atherosclerosis stenosis, which will help us find out the etiology of stroke. Previous studies have demonstrated its prognosis value in predicting recurrent stroke in the same vascular territory. The investigators hypothesize that with an appropriate evaluation, HR-MRI could help to predict recurrent stroke in the same vascular territory in patients with high-risk plaque characteristics on HR-MRI. These findings could contribute to individual treatment according to etiology.\n\nThe investigators intend to conduct a study to determine the correlation between plaque characteristics and recurrent stroke in the same vascular territory in ischemic stroke patients due to middle cerebral artery stenosis.",[25,26,27,28,29],"High Resolution Vessel Wall Imaging","Recurrent Stroke","Stroke, Mechanism","Atheroscleroses, Intracranial","Stroke, Infarct Pattern","RECRUITING","2026-08-03",{"date":33,"type":34},"2026-08-06","ACTUAL",{"date":36,"type":34},"2024-05-27",{"date":38,"type":21},"2026-12",{"name":40,"class":41},"University Medical Center Ho Chi Minh City (UMC)","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100508997","medical-treatment-with-or-without-transcatheter-patent-foramen-ovale-closure-100508997","NCT05907694","Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure","Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial","STOP","Inclusion Criteria:\n\n* Cryptogenic stroke\n* Age \\>60 years\n* Right-to-left shunt as evaluated by echocardiography (TEE).\n\nExclusion Criteria:\n\n-≤60 year-old\n\n* Lacunar (small vessel) stroke.\n* Permanent or paroxysmal atrial fibrillation\u002Fflutter (clinically apparent or detected by continuous ECG monitoring).\n* Need for chronic anticoagulation therapy.\n* Any contraindication for antiplatelet therapy (aspirin, clopidogrel, ticagrelor).\n* Presence of extracranial or intracranial atherosclerosis causing ≥50% luminal --stenosis in arteries supplying the area of ischemia.\n* Presence of complex atheroma plaques at the ascending aorta-aortic arch (≥4-mm-thick, ulcerated or containing mobile thrombi) as evaluated by TEE.\n* Presence of intracardiac thrombus as evaluated by TEE.\n* Uncontrolled hypertension (systemic pressure values \\>160\u002F90 mmHg despite optimal medical treatment).\n* History of myocardial infarction or coronary intervention. (percutaneous coronary intervention, coronary artery bypass graft).\n* History of prior valve surgery or transcatheter valve repair.\n* Presence of deep venous thrombosis at the time of index stroke as evaluated by Doppler ultrasonography.\n* Left ventricular ejection fraction \\\u003C50% as evaluated by TTE.\n* Significant (moderate or severe) valvular disease as evaluated by echocardiography.\n* History of congestive heart failure.\n* Severe chronic kidney dysfunction defined an estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002Fm2 or need for dialysis.\n* Isolated ASD or ASD associated with PFO but with a hemodynamically significant left-to-right shunt requiring closure.\n* Other specific cause of stroke identified (eg, arteritis, dissection, migraine\u002Fvasospasm, and drug abuse).\n* Prior surgical or endovascular treatments of PFO or ASD.\n* Rheumatic heart disease.\n* Left atrial enlargement defined as a left atrial diameter \\>41 mm in men and ≥39 mm in women.\n* Presence of high burden of premature atrial contractions (\\>500 per 24 hrs) as evaluated by continuous ECG monitoring.\n* Follow-up impossible or expected poor compliance.\n* Active cancer.\n* Presence of an inferior vena cava filter.\n* Severe pulmonary artery hypertension (systolic pulmonary pressure \\>60 mmHg).\n* Functional dependency as measured by a modified Rankin Scale score \\>3 (unable to attend to own bodily needs without assistance and unable to walk unassisted).\n* Any medical condition determining a life expectancy \\\u003C2 years.\n* Participation in another randomized study.\n* Failure to provide signed informed consent.","18 Years",{"count":53,"type":21},714,"INTERVENTIONAL",[56],"NA","Patent foramen ovale PFO closure has been shown to reduce the risk of stroke in patients with recurrent stroke. However, the majority of existing clinical studies in this field excluded patients over the age of 60 years. Data in older patients is limited and since the population ages and stroke remains a major cause of death and morbidity, randomized clinical trials are needed to better assess the benefit of PFO closure in this elderly population. Therefore, this study proposal sought to determine the efficacy of PFO closure for the prevention of recurrent stroke in older patients with PFO and cryptogenic stroke.",[59,60,61,62,26],"Patent Foramen Ovale","Cryptogenic Stroke","Older Patients","Medical Treatment","2026-03-23",{"date":65,"type":34},"2026-03-27",{"date":67,"type":34},"2024-06-18",{"date":69,"type":21},"2037-10-01",{"name":71,"class":41},"Josep Rodes-Cabau",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":54,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":42},"100606350","phase-3-cilostazol-for-prevention-of-recurrent-stroke-trial-100606350","NCT07174414","Cilostazol for Prevention of Recurrent Stroke Trial","Clarity","Inclusion Criteria:\n\n* Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days\n* Currently taking aspirin or clopidogrel (not both) to prevent another stroke\n\nExclusion Criteria:\n\n* Had a spontaneous brain bleed within the last 2 years.\n* Moderate to severe heart failure.\n* Life expectancy is less than 6 months.","40 Years",{"count":82,"type":21},2000,[84],"PHASE3","The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.",[87,88,89,90,91,92,26],"Stroke Recurrence","Myocardial Infarction","Vascular Death","Ischemic Stroke","TIA (Transient Ischemic Attack)","Stroke (CVA) or Transient Ischemic Attack","NOT_YET_RECRUITING","2025-09-12",{"date":96,"type":34},"2025-09-16",{"date":98,"type":21},"2026-08",{"date":100,"type":21},"2031-07",{"name":102,"class":41},"Stanford University"]